Home › Research › Clinical trials
Sativex (nabiximols) for the treatment of Agitation & Aggression in Alzheimer's dementia in UK nursing homes: a randomised, double-blind, placebo-controlled feasibility trial
Albertyn CP, Guu TW, Chu P, Creese B, Young A, Velayudhan L, Bhattacharyya S, Jafari H, Kaur S, Kandangwa P, et al.. Age and Ageing, 2025-05-31
Topic: Risk, prevention and care in population studies
Plain-language summary
Background Alzheimer's Disease (ad) patients often experience clinically significant agitation, leading to distress, increased healthcare costs and earlier institutionalisation. Current treatments have limited efficacy and significant side effects. Cannabinoid-based therapies, such as the nabiximols oral spray (Sativex®; 1:1 delta-9-tetrahydrocannabinol and cannabidiol), offer potential alternatives. We aimed to explore the feasibility and safety of nabiximols as a potential treatment for agitation in ad. Methods The 'Sativex® for Agitation & Aggression in Alzheimer's Dementia' (STAND) trial was a randomised, double-blind, placebo-controlled, feasibility study conducted in UK care homes. Participants with probable ad and predefined clinically significant agitation were randomised to receive placebo or nabiximols for 4 weeks on an up-titrated schedule, followed by a 4-week observation period. To be considered feasible, we prespecified the following thresholds that needed to be met: randomising 60 participants within 12 months, achieving a ≥ 75% follow-up rate at 4 weeks, maintaining ≥80% adherence to allocation and estimating a minimum effect size (Cohen's d ≥ 0.3) on the Cohen-Mansfield Agitation Inventory. This trial is registered with ISRCTN 7163562. Findings Between October 2021 and June 2022, 53 candidates were assessed; 29 met eligibility criteria and were randomised. No participants withdrew, and adherence was high (100%) and was generally feasible to deliver. The intervention was well tolerated (0 adverse reactions), with no safety concerns reported. Interpretation Despite significant COVID-19 pandemic related challenges, administering nabiximols through oral mucosa to advanced ad patients with agitation demonstrated feasibility and safety. These findings support a larger confirmatory efficacy trial to evaluate the potential therapeutic efficacy of nabiximols for agitation in ad.
What this study adds
Evidence grade: Preliminary
The record lists 29 participants. This feasibility trial of nabiximols for agitation in Alzheimer's dementia did not meet its prespecified feasibility thresholds. Its stated limit: Only 29 participants; recruitment target missed; not powered for efficacy; 4-week treatment period.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Albertyn, C. P., Guu, T. W., Chu, P., Creese, B., Young, A., Velayudhan, L., et al. (2025). Sativex (nabiximols) for the treatment of Agitation & Aggression in Alzheimer's dementia in UK nursing homes: a randomised, double-blind, placebo-controlled feasibility trial. Age and Ageing. https://doi.org/10.1093/ageing/afaf149
Vancouver
Albertyn CP, Guu TW, Chu P, Creese B, Young A, Velayudhan L, et al. Sativex (nabiximols) for the treatment of Agitation & Aggression in Alzheimer's dementia in UK nursing homes: a randomised, double-blind, placebo-controlled feasibility trial. Age and Ageing. 2025. doi:10.1093/ageing/afaf149. PMID: 40479610.
BibTeX
@article{albertyn2025-40479610,
author = {Albertyn, C. P. and Guu, T. W. and Chu, P. and Creese, B. and Young, A. and Velayudhan, L. and Bhattacharyya, S. and Jafari, H. and Kaur, S. and Kandangwa, P. and others},
title = {{Sativex (nabiximols) for the treatment of Agitation \& Aggression in Alzheimer's dementia in UK nursing homes: a randomised, double-blind, placebo-controlled feasibility trial}},
journal = {Age and Ageing},
year = {2025},
doi = {10.1093/ageing/afaf149},
pmid = {40479610},
url = {https://doi.org/10.1093/ageing/afaf149}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Background Alzheimer's Disease (ad) patients often experience clinically significant agitation, leading to distress, increased healthcare costs and earlier institutionalisation.
- Current treatments have limited efficacy and significant side effects.
- Participants with probable ad and predefined clinically significant agitation were randomised to receive placebo or nabiximols for 4 weeks on an up-titrated schedule, followed by a 4-week observation period.
- Interpretation Despite significant COVID-19 pandemic related challenges, administering nabiximols through oral mucosa to advanced ad patients with agitation demonstrated feasibility and safety.
- These findings support a larger confirmatory efficacy trial to evaluate the potential therapeutic efficacy of nabiximols for agitation in ad.
Why it matters
This feasibility trial of nabiximols for agitation in Alzheimer's dementia did not meet its prespecified feasibility thresholds. It was designed to explore feasibility and safety, not to test efficacy.
New to this subject? Start with our plain-English guide: Registered clinical trials →
Study details
- Study designRCT
- Participants29
- Evidence strengthPreliminary
Limitations
Only 29 participants; recruitment target missed; not powered for efficacy; 4-week treatment period.
How this study scored 59/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it. We have no data on free to read, so that was left out: it earned 58 of the 98 points we could judge it on, which is 59 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Age and Ageing) |
| Journal's citation record | 2 / 4 | Age and Ageing: journal h-index 231 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial |
| Strength of evidence | 2 / 5 | Rated “preliminary” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 29 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 2 / 7 | Cited 7 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Dag Aarsland: h-index 141 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | King's College London: institution h-index 1,348 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 4 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40479610) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 58 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 58 of the 98 points we could judge it on is 59 out of 100. |
| Total | 59 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Clinical trials from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.